1. Introduction {#sec1-cells-09-01480}
===============

Prion diseases are fatal and irreversible neurodegenerative diseases caused by a deleterious form of the prion protein (PrP^Sc^) derived from normal prion protein (PrP^C^) \[[@B1-cells-09-01480],[@B2-cells-09-01480]\]. These diseases are accompanied by spongiform generation and astrocytosis in brain lesions. Prion diseases are the only zoonotic dementia with such a large host ranges, including scrapie in sheep and goats, bovine spongiform encephalopathy (BSE) in cattle, chronic wasting disease (CWD) in elk and deer, and Creutzfeldt--Jakob disease (CJD), fatal familial insomnia (FFI), and Gerstmann--Sträussler--Scheinker syndrome (GSS) in humans. In CJD, there are three representative types, including sporadic CJD, familial CJD, and iatrogenic CJD \[[@B3-cells-09-01480],[@B4-cells-09-01480],[@B5-cells-09-01480],[@B6-cells-09-01480],[@B7-cells-09-01480],[@B8-cells-09-01480],[@B9-cells-09-01480],[@B10-cells-09-01480],[@B11-cells-09-01480],[@B12-cells-09-01480]\].

It has been approximately three centuries since scrapie in sheep was first discovered in 1732 \[[@B5-cells-09-01480]\]. However, the exact roles on certain factors influencing the causative agent of the disease have not been fully explained thus far. However, in recent studies, genetic variations including somatic mutations or postzygotic mutations have been shown to cause several diseases, including neurofibromatosis, McCune--Albright disease, paroxysmal nocturnal hemoglobinuria, incontinentia pigmenti, several types of cancer, and Alzheimer's disease \[[@B13-cells-09-01480],[@B14-cells-09-01480],[@B15-cells-09-01480]\]. In human prion diseases, point mutations in the prion protein gene (*PRNP*), which encodes PrP, induce familial forms of human prion diseases, including familial CJD, GSS, and FFI \[[@B6-cells-09-01480],[@B16-cells-09-01480],[@B17-cells-09-01480]\]. In addition, spontaneous *de novo* mutations in the *PRNP* gene were detected in several types of prion diseases, including sporadic CJD and GSS \[[@B18-cells-09-01480],[@B19-cells-09-01480],[@B20-cells-09-01480],[@B21-cells-09-01480]\]. In this regard, somatic mutations in the *PRNP* gene can be assumed to be a cause of prion diseases. In addition, previous studies have been reported that cancer tissues showed more genetic instability and elevated expression of the *PRNP* gene. Thus, we postulated that cancer tissue may induce somatic mutations in the *PRNP* gene, which can trigger the onset of prion diseases \[[@B22-cells-09-01480],[@B23-cells-09-01480],[@B24-cells-09-01480],[@B25-cells-09-01480]\].

To find somatic mutations in the *PRNP* gene in cancer tissues, we searched the information on somatic mutations in the *PRNP* gene in cancer patients using the Cancer Genome Atlas (TCGA) database \[[@B26-cells-09-01480]\]. In addition, we compared the information on the somatic mutations in the *PRNP* gene in cancer patients with that of previously reported pathogenic mutations associated with prion diseases and with the total cancer patient population. Furthermore, to assess whether the somatic mutations in the *PRNP* gene in cancer patients are deleterious, we performed *in silico* annotation using PolyPhen-2, PANTHER, PROVEAN, and AMYCO \[[@B27-cells-09-01480],[@B28-cells-09-01480],[@B29-cells-09-01480],[@B30-cells-09-01480],[@B31-cells-09-01480],[@B32-cells-09-01480]\].

2. Results {#sec2-cells-09-01480}
==========

2.1. Previously Reported Prion Disease-Related Mutations {#sec2dot1-cells-09-01480}
--------------------------------------------------------

Genetic forms of human prion diseases include CJD, FFI, and GSS. Previous pathogenic mutations involved in genetic forms of prion diseases are described in [Table 1](#cells-09-01480-t001){ref-type="table"}. In detail, genetic CJD has been reported to carry G114V, D178N-129V, V180I, T183A, T188K, E196K, E196A, E200K, E200G, V203I, R208H, V210I, E211Q, I215V, M232R, and P238S mutations; double octapeptide deletions; and octapeptide insertions in the *PRNP* gene. In addition, FFI has been reported to carry D178N-129M mutations in the *PRNP* gene. Finally, GSS has been reported to carry P102L, P105L, P105T, P105S, A117V, G131V, Y145\*, Q160\*, V176G, H187R, F198S, D202N, Q212P, Q217R, Y226\*, Q227\*, and M232T mutations in the *PRNP* gene. Unique phenotypes of dementia have been reported to carry S17G, P39L, Y163\*, D167N, D187fs, and R208C mutations in the *PRNP* gene.

2.2. 48 Somatic Mutations in the PRNP Gene in Cancer Patients {#sec2dot2-cells-09-01480}
-------------------------------------------------------------

Using cBioPortal, we identified a total of 48 somatic mutations in the *PRNP* gene in 10,953 cancer patients. The detailed information is described in [Table 2](#cells-09-01480-t002){ref-type="table"}. Among the 48 mutations, 8 mutations, these being G131V, D167N, V180I, D202N, V203I, R208C, R208H, and E211Q (shaded boxes), were previously reported pathogenic mutations of prion diseases ([Table 1](#cells-09-01480-t001){ref-type="table"}). The locations of the identified somatic mutations are visualized in [Figure 1](#cells-09-01480-f001){ref-type="fig"}. A total of five somatic mutations, these being M1X, G5A, L11I, W16S, and D18N, were located in the N-terminal signal peptide region. A total of five somatic mutations, including R25C, P26L, G34R, and G35A (fs), were located in the region of codons 23--51. A total of four somatic mutations, these being H61Y, Q75S (fs), H85N, and G86S, were located in an octapeptide repeat region. A total of 30 somatic mutations, these being G92E, G92X, K104E, G119R, L125F, M129T, G131V, G131R, Y145C, E146Q, R148H, R151C, M166I, D167N, N173H, H177N, V180I, E196R (FS), D202N, V203I, K204N, R208C, R208H, V209M, E211Q, C214G, Q217K, Y218C, E221G, and S230L, were located in the proteinase K resistant core region. Finally, two somatic mutations, I244F and V252L, were located in the C-terminal signal peptide region. Notably, of the 25 patients for whom we had access to cancer metastasis information, we observed no evidence of distant metastasis in 22 (92%) of them ([Table 2](#cells-09-01480-t002){ref-type="table"}).

In addition, we compared the information on cancer patients who carried somatic mutations of the *PRNP* gene with that of the total cancer patient population. The detailed information is described in [Table 3](#cells-09-01480-t003){ref-type="table"}. In detail, we found 48 *PRNP* somatic mutations carriers (subgroup 1) and 8 *PRNP* pathogenic somatic mutation carriers of prion disease (subgroup 2). Subgroup 1 accounts for 0.43% of the total cancer patient population assessed, while subgroup 2 accounts for 0.07% of the total cancer patient population. Subgroup 2 accounts for 17.02% of subgroup 1. The age of diagnosis in the total cancer patient population was 59.1 ± 14.5 years, in subgroup 1 was 66 ± 12.8 years, and in subgroup 2 was 66.3 ± 7.8 years. Notably, compared to the age of diagnosis in the total cancer patient population, those of subgroups 1 showed significant differences with *p*-values of 0.000742. In addition, there were also significant differences in the mutation count distributions between the total cancer patient population and subgroups 1 and 2, with *p*-values \< 0.00001 and 2.3 × 10^−11^, respectively. Specifically, a large number of the total cancer patient population displayed mutation counts \<100 (67.3%). By contrast, subgroups 1 and 2 primarily displayed mutation counts \>280 (83.3% and 100%, respectively). The distribution of cancer type between the total cancer patient population and subgroup 1 showed statistical significance. (*p* = 6 × 10^−12^). Specifically, the percentage of non-small cell lung cancer patients in subgroup 1 (16.7%) was increased by 1.7-fold compared to the total cancer patient population (9.6%). The percentage of endometrial carcinoma patients in subgroup 1 (33.3%) was increased by 6.3-fold compared to the total cancer patient population (5.3%). The percentage of non-small cell lung cancer patients in subgroup 2 (12.5%) was increased by 1.3-fold compared to the total cancer patient population (9.6%). The percentage of colorectal adenocarcinoma patients in subgroup 2 (12.5%) was increased by 2.3-fold compared to the total cancer patient population (5.4%). The percentage of endometrial carcinoma patients in subgroup 2 (25.0%) was increased by 4.7-fold compared to the total cancer patient population (5.3%). Notably, although invasive breast carcinoma and glioblastoma account for a high percentage of the total cancer patient population (9.9% and 5.4%, respectively), somatic mutations in the *PRNP* gene have not been identified in these two cancer types. Strikingly, distributions of six major cancer types (invasive breast cancer, non-small cell lung cancer, colorectal adenocarcinoma, glioblastoma, endometrial carcinoma, and ovarian epithelial tumor) of the patients with somatic mutations of the *PRNP* gene were shown to be significantly different from distributions of the six major cancer types of total patients ([Figure 2](#cells-09-01480-f002){ref-type="fig"}).

2.3. In Silico Annotation of Mutations in the PRNP Gene {#sec2dot3-cells-09-01480}
-------------------------------------------------------

The impact of somatic mutations in PrP identified in this study and previously reported pathogenic mutations was analyzed by PolyPhen-2, PANTHER, and PROVEAN. The detailed information is described in [Table 4](#cells-09-01480-t004){ref-type="table"}. Notably, six somatic mutations, these being P26L, G34R, G119R, G131V, C214G, and Y218C, and five pathogenic mutations, these being P102L, P105L, G114V, H187R, and E200G were predicted to be deleterious by all three programs. We also evaluated the amyloid propensity of the mutations in the *PRNP* gene by AMYCO. The detailed information is described in [Figure 3](#cells-09-01480-f003){ref-type="fig"}. Interestingly, nine mutations, these being L125F, G131V, E146Q, R151C, D167N, D178N-129M, D178N-129V, D187fs, and K204N, had an increased amyloid propensity with values of 0.23, 0.23, 0.23, 0.27, 0.27, 0.13, 0.13, 0.18, and 0.36, respectively. Among the six somatic mutations of cancer patients, four were newly identified amyloid-prone somatic mutations---L125F, E146Q, R151C, and K204N.

3. Discussion {#sec3-cells-09-01480}
=============

In the present study, we identified a total of 48 somatic mutations in the *PRNP* gene in 10,967 cancer patients. Prion diseases are considered to be monogenic diseases, and the association of the *PRNP* gene with the onset of prion diseases was confirmed by genome-wide association studies (GWAS) \[[@B33-cells-09-01480],[@B34-cells-09-01480]\]. Thus, the somatic mutations in the *PRNP* gene in cancer tissues are very important. Of the 48 somatic mutations, 8 were previously confirmed pathogenic mutations of prion diseases. Although we cited pathogenic mutations of the *PRNP* gene from previous studies, the penetrance on the pathogenic mutations of the *PRNP* gene was still debatable. In a previous study, several mutations including V180I, V210I, and M232R were found in healthy controls and these mutations showed low penetrance under 10%. Thus, these results suggest that these mutations were benign variants or low-risk variants \[[@B35-cells-09-01480]\]. In the present study, we further analyzed previously reported pathogenic mutations using *in silico* programs. Notably, V180I, V210I, and M232R mutations were predicted to be low amyloid propensity and benign by some programs ([Figure 3](#cells-09-01480-f003){ref-type="fig"}, [Table 4](#cells-09-01480-t004){ref-type="table"}). Further study to confirm the deleterious effects of the mutations is needed in the future. In addition, cancer patients carrying these somatic mutations showed no evidence of distant metastasis ([Table 2](#cells-09-01480-t002){ref-type="table"}). Since PrP contributes to metastasis in several types of cancers, somatic mutations of the *PRNP* gene, which can affect normal function of PrP, may impact the property of distant metastasis \[[@B36-cells-09-01480],[@B37-cells-09-01480]\]. Further validation of distant metastatic property in cancer cells carrying *PRNP* mutations is highly desirable in the future. Interestingly, the age of patients carrying somatic mutations (66 ± 12.8 years) was much older than that of the total cancer patient population (59.1 ± 14.5 years) ([Table 2](#cells-09-01480-t002){ref-type="table"}). Since sporadic prion disease has been reported to develop around the ages of 60--70, this was a very interesting finding \[[@B38-cells-09-01480]\]. In addition, since PrP contributes to several properties of cancer including tumorigenesis, protection of apoptotic stress, and metastasis, further study of the relationship between age and several characteristics of cancers mediated by somatic mutations of the *PRNP* gene is needed in the future \[[@B36-cells-09-01480],[@B37-cells-09-01480],[@B39-cells-09-01480],[@B40-cells-09-01480]\]. Furthermore, 83.3% of patients carrying somatic mutations of the *PRNP* gene showed over 280 mutation counts. This distribution is significantly different from that of the total cancer patient population. In addition, the cancer type of the patients carrying somatic mutations was also significantly different from the total cancer patient population. Notably, although invasive breast carcinoma (9.9%) and glioblastoma (5.4%) account for high percentage of the total cancer patient population, somatic mutation of the *PRNP* gene has not been identified in these two cancer types. Specifically, because somatic mutations of the *PRNP* gene in glioblastoma, which occurs in the brain, can be masked by a diagnosis of dementia, the absence of somatic mutations in the *PRNP* gene in glioblastoma can be explained. Previous study has been reported that transgenic mice carrying a pathogenic mutation of the *PRNP* gene can lead to spontaneous prion disease \[[@B41-cells-09-01480],[@B42-cells-09-01480]\]. In addition, a recent study has been reported that PrP^Sc^ were also detected in healthy people, who have not been diagnosed with prion diseases \[[@B43-cells-09-01480]\]. On the basis of these studies, we postulated that cancer patients carrying pathogenic somatic mutation of the *PRNP* gene may produce a basal level of PrP^Sc^ in peripheral tissues and may not be diagnosed with prion disease. However, to date, there is no clinical evidence for this hypothesis. Since PrP protects cancer cells against apoptotic stress and contributes to tumorigenesis, the difference on distribution of somatic mutation of the *PRNP* gene may be induced depending on the degree of contribution of PrP to different cancer types \[[@B39-cells-09-01480],[@B40-cells-09-01480]\]. Further study to verify functional role of prion protein in various cancer types is needed in the future.

We also analyzed somatic mutations of the *PRNP* gene in cancer patients by PolyPhen-2, PANTHER, and PROVEAN. Notably, six somatic mutations---P26L, G34R, G119R, G131V, C214G, and Y218C---and five pathogenic mutations---P102L, P105L, G114V, H187R, and E200G---were considered to be damaging to PrP function by all three programs. Since PrP^C^ has also been reported to be related to the survival signaling pathway and copper ion-associated enzyme activity, these somatic mutations may impact the normal function of PrP \[[@B44-cells-09-01480]\]. In addition, we predicted the amyloid propensity of the somatic mutations in the *PRNP* gene in cancer patients. Notably, four somatic mutations---L125F, E146Q, R151C, and K204N---were newly identified amyloid-prone somatic mutations in the *PRNP* gene in cancer patients. In addition, we found several nonsense somatic mutations. These nonsense mutations induced PrP cleavage, which can affect the survival signaling pathway or the aggregation of PrP \[[@B6-cells-09-01480],[@B17-cells-09-01480],[@B45-cells-09-01480]\]. Thus, further investigation of the mutation counts, the absence of somatic mutations in glioblastoma, and these nonsense mutations are highly desirable in the future.

In recent cancer studies, p53 has been demonstrated to play a pivotal role in several types of cancer and showed prion-like aggregation. Aggregation of p53 causes additional deleterious effects in cancer patients \[[@B46-cells-09-01480],[@B47-cells-09-01480],[@B48-cells-09-01480]\]. In addition, although cross-seeding activity between aggregated p53 and PrP^Sc^ has not been investigated thus far, the similarity of cross-seeding activities in other misfolded proteins suggests that aggregated p53 may act as a seed to induce the aggregation of PrP \[[@B49-cells-09-01480]\]. Thus, the detection of PrP^Sc^ in cancer patients using Western blot or protein misfolded cyclic amplification (PMCA) is highly desirable in the future.

4. Material and Methods {#sec4-cells-09-01480}
=======================

4.1. Information on the Somatic Mutations in the PRNP Gene in Cancer Patients {#sec4dot1-cells-09-01480}
-----------------------------------------------------------------------------

The protein sequence of human PrP in [Figure 1](#cells-09-01480-f001){ref-type="fig"} was obtained from GenBank at the National Center for Biotechnology Information (NCBI, AAH22532.1). Previously reported pathogenic mutations associated with prion disease were collected from previous studies \[[@B6-cells-09-01480],[@B16-cells-09-01480],[@B17-cells-09-01480]\]. The data on somatic mutations of the *PRNP* gene in cancer patients were extracted from TCGA database using cBioPortal (<http://www.cbioportal.org/>) \[[@B26-cells-09-01480]\]. Among total mutations of the *PRNP* gene, germline mutations were excluded using the filtering option. Somatic mutations were analyzed using reference sequence from GenBank at the NCBI (NM_000311.5). Clinical data including somatic mutations, age of diagnosis, sex, mutation count, cancer type, and allele frequencies were retrieved from cBioPortal and the data were read by R (<https://www.r-project.org/>).

4.2. Statistical Analysis {#sec4dot2-cells-09-01480}
-------------------------

Statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). The differences in the distributions of sex, mutation count, and cancer type between the total cancer patient population and the subgroups were compared using the χ^2^ test. The age of diagnosis was reported as the mean values ± standard deviation (SD). Statistical significance based on *p*-values was calculated with a one-tailed Student's *t*-test for single comparison.

4.3. In Silico Evaluation of Somatic Mutations in the PRNP Gene in Cancer Patients {#sec4dot3-cells-09-01480}
----------------------------------------------------------------------------------

Somatic mutations in the *PRNP* gene in cancer patients were evaluated by PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/>), PANTHER (<http://www.pantherdb.org/>), PROVEAN (<http://provean.jcvi.org/index.php>), and AMYCO (<http://bioinf.uab.es/amycov04/>) \[[@B27-cells-09-01480],[@B28-cells-09-01480],[@B29-cells-09-01480],[@B30-cells-09-01480]\]. The effects of sequence variation were evaluated on the basis of protein structure by PolyPhen-2. The PolyPhen-2 score corresponds to the substitution effect and ranges from 0.0 to 1.0. The prediction outcome can be presented as "Benign", "Possibly damaging", or "Probably damaging" on the basis of the score. PROVEAN assessed amino acid substitution by building up and comparing the clusters of related sequences and calculating the score. Scores below −2.5 are predicted as "Deleterious" and scores above −2.5 are predicted as "Neutral". PANTHER analyzes data in groups on the basis of similarities in molecular function and biological processes. PANTHER analyzed preservation time to estimate the substitution of amino acids. The interpretation of preservation time is described as follows: "Probably damaging" is greater than 450; "Possibly damaging" is between 200 and 450; "Probably benign" is less than 200. AMYCO evaluates the impact of variations on the aggregation propensity of prion-like proteins. The AMYCO score corresponds to the substitution effect and ranges from 0.0 to 1.0.

5. Conclusions {#sec5-cells-09-01480}
==============

In conclusion, we identified 48 somatic mutations in the *PRNP* gene in 10,967 cancer patients. Among them, eight somatic mutations are pathogenic for prion diseases. We identified significantly different distributions of cancer type, mutation count, and the age of diagnosis between the total cancer patient population and cancer patients carrying *PRNP* somatic mutations. We found six somatic mutations, these being P26L, G34R, G119R, G131V, C214G, and Y218C, and five pathogenic mutations, these being P102L, P105L, G114V, H187R, and E200G, which can affect PrP^C^ function, along with four aggregation-prone somatic mutations---L125F, E146Q, R151C, and K204N. To the best of our knowledge, this is the first specific analysis on the somatic mutations of the *PRNP* gene in cancer patients.

The results obtained in this study are partially based on data produced by the TCGA Research Network (<http://cancergenome.nih.gov/>).
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###### 

Prediction on amyloid propensity of prion protein (PrP) according to somatic mutations of the prion protein gene (*PRNP*) gene in cancer patients. ^\$^ indicates somatic mutations of the *PRNP* gene in cancer patients. ^\#^ indicates previously reported pathogenic mutations of the *PRNP* gene in prion diseases.
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cells-09-01480-t001_Table 1

###### 

Classification of pathogenic mutations of prion disease according to clinical phenotypes in previous studies.

  Clinical Phenotypes                               Mutations
  ------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Creutzfeldt--Jakob Disease (CJD)                  G114V, D178N-129V, V180I, T183A, T188K, E196K, E196A, E200K, E200G, V203I, R208H, V210I, E211Q, I215V, M232R, P238S, double octapeptide deletion, and octapeptide insertions
  Fatal familial insomnia (FFI)                     D178N-129M
  Gerstmann--Sträussler--Scheinker syndrome (GSS)   P102L, P105L, P105T, P105S, A117V, G131V, Y145\*, Q160\*, V176G, H187R, F198S, D202N, Q212P, Q217R, Y226\*, Q227\*, and M232T
  Others                                            S17G, P39L, Y163\*, D167N, D187fs, and R208C

Others: includes unique phenotypes of dementia. \*: stop codon. fs: frame shift.

cells-09-01480-t002_Table 2

###### 

Detailed information on the 48 somatic mutations in cancer patients.

  Sample ID         Sex   Age   Cancer Type                                 AJCCMSC   AJCCTSC   Mutation      Mutation Type     Allele Frequency   \# Mut
  ----------------- ----- ----- ------------------------------------------- --------- --------- ------------- ----------------- ------------------ --------
  TCGA-4Z-AA7Q-01   M     79    Bladder urothelial carcinoma                M0        T3A       E146Q         Missense          0.19               222
  TCGA-5N-A9KM-01   F     73    Bladder urothelial carcinoma                MX        T4A       M1?           Nonstart          0.36               189
  TCGA-IR-A3LK-01   F     69    Cervical squamous cell carcinoma            M0        T1B2      G131V         Missense          0.14               1189
  TCGA-KN-8428-01   M     71    Chromophobe renal cell carcinoma            NA        T2        V203I         Missense          0.20               673
  TCGA-CK-5916-01   F     71    Colon adenocarcinoma                        M0        T1        V180I         Missense          0.25               1407
  TCGA-EE-A29V-06   M     85    Cutaneous melanoma                          M0        T3B       G92E          Missense          0.42               1012
  TCGA-EB-A41A-01   M     90    Cutaneous melanoma                          M0        T4B       L125F         Missense          0.44               1533
  TCGA-D3-A2JC-06   F     53    Cutaneous melanoma                          M0        T0        M166I         Missense          0.11               3148
  TCGA-D3-A8GM-06   M     73    Cutaneous melanoma                          M0        T3B       G86S          Missense          0.09               3288
  TCGA-YD-A9TA-06   M     75    Cutaneous melanoma                          NA        NA        H61Y          Missense          0.29               2782
  TCGA-L5-A43J-01   M     90    Esophageal squamous cell carcinoma          MX        T3        R25C          Missense          0.20               700
  TCGA-F7-A624-01   M     73    Head and neck squamous cell carcinoma       M0        T2        R208H         Missense          0.16               2744
  TCGA-VQ-A91D-01   M     70    Intestinal type stomach adenocarcinoma      M0        T4B       R208C         Missense          0.25               2140
  TCGA-67-3771-01   F     77    Lung adenocarcinoma                         M0        T1        N173H         Missense          0.12               951
  TCGA-44-5644-01   F     51    Lung adenocarcinoma                         NA        T2A       G5A           Missense          0.34               908
  TCGA-69-A59K-01   F     60    Lung adenocarcinoma                         M0        T3        G119R         Missense          0.21               438
  TCGA-17-Z023-01   NA    NA    Lung adenocarcinoma                         NA        NA        Y49C          Missense          0.23               362
  TCGA-17-Z026-01   NA    NA    Lung adenocarcinoma                         NA        NA        E211Q         Missense          0.19               873
  TCGA-22-5489-01   M     64    Lung squamous cell carcinoma                M0        T1B       Y145C         Missense          0.21               227
  TCGA-63-A5MM-01   F     69    Lung squamous cell carcinoma                M0        T2        H177N         Missense          0.23               1070
  TCGA-NC-A5HH-01   M     53    Lung squamous cell carcinoma                M0        T1        W16S          Missense          0.27               314
  TCGA-G7-6790-01   M     57    Papillary renal cell carcinoma              MX        T1A       Q217K         Missense          0.09               71
  TCGA-F9-A97G-01   M     79    Papillary renal cell carcinoma              M0        T3        V252L         Missense          0.20               62
  TCGA-AG-A002-01   M     35    Rectal adenocarcinoma                       M0        T2        P26L          Missense          0.45               11,438
  TCGA-B0-5713-01   F     75    Renal clear cell carcinoma                  M0        T3B       E221G         Missense          0.30               97
  TCGA-25-1313-01   F     62    Serous ovarian cancer                       NA        NA        G131R         Missense          0.37               179
  TCGA-VQ-A8PO-01   M     74    Signet ring cell carcinoma of the stomach   M0        T4A       M129T         Missense          0.23               751
  TCGA-BR-6452-01   F     78    Stomach adenocarcinoma                      M0        T3        I244F         Missense          0.19               5050
  TCGA-CG-5717-01   M     58    Stomach adenocarcinoma                      M0        T2B       R151C         Missense          0.34               117
  TCGA-CG-5723-01   M     83    Stomach adenocarcinoma                      M0        T2        V209M         Missense          0.08               1606
  TCGA-VQ-A8PP-01   M     76    Tubular stomach adenocarcinoma              M0        T4        K104E         Missense          0.36               1328
  TCGA-DX-AB2Z-01   F     87    Undifferentiated pleomorphic sarcoma        NA        NA        R148H         Missense          0.11               69
  TCGA-N7-A4Y0-01   F     65    Uterine carcinosarcoma                      NA        NA        C214G         Missense          0.64               709
  TCGA-ND-A4WC-01   NA    NA    Uterine carcinosarcoma                      NA        NA        H85N          Missense          0.20               3669
  TCGA-B5-A0JY-01   F     50    Uterine endometrioid carcinoma              NA        NA        K204N         Missense          0.34               9713
  TCGA-D1-A17Q-01   F     54    Uterine endometrioid carcinoma              NA        NA        D167N         Missense          0.40               5945
  TCGA-AP-A1DV-01   F     59    Uterine endometrioid carcinoma              NA        NA        R25C          Missense          0.52               12,071
  TCGA-FI-A2D5-01   F     56    Uterine endometrioid carcinoma              NA        NA        D202N         Missense          0.38               13,874
  TCGA-AJ-A3EL-01   F     47    Uterine endometrioid carcinoma              NA        NA        L11I          Missense          0.40               7391
  TCGA-AP-A0LT-01   F     57    Uterine endometrioid carcinoma              NA        NA        E196Rfs\*10   Frame shift del   0.28               638
  TCGA-AP-A1DV-01   F     59    Uterine endometrioid carcinoma              NA        NA        Y218C         Missense          0.42               12,071
  TCGA-AX-A3FT-01   F     64    Uterine endometrioid carcinoma              NA        NA        Q75Sfs\*35    Frame shift del   0.23               1281
  TCGA-B5-A1MX-01   F     47    Uterine endometrioid carcinoma              NA        NA        G92\*         Nonsense          0.33               5699
  TCGA-BG-A222-01   F     49    Uterine endometrioid carcinoma              NA        NA        G34R          Missense          0.45               4276
  TCGA-DF-A2KU-01   F     NA    Uterine endometrioid carcinoma              NA        NA        S230L         Missense          0.30               10,058
  TCGA-EO-A22R-     F     56    Uterine endometrioid carcinoma              NA        NA        S230L         Missense          0.30               12,783
  TCGA-EY-A1GK-01   F     74    Uterine endometrioid carcinoma              NA        NA        G35Afs\*75    Frame shift del   0.30               841
  TCGA-A5-A0G2-01   F     57    Uterine serous carcinoma                    NA        NA        D18N          Missense          0.18               25,730

AJCCMSC: American Joint Committee on Cancer Metastasis Stage Code. AJCCTSC: American Joint Committee on Cancer Tumor Stage Code. \# Mut: Total number of non-synonymous mutation in the sample. M0: No evidence of distant metastasis. MX: Distant metastasis cannot be assessed. NA: Not available. Shaded boxes indicate pathogenic somatic mutations of prion diseases. \*: stop codon.
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###### 

Summary of information on the cancer patients carrying somatic mutations in the *PRNP* gene.

  Characteristics                                                         All Cancer Patients   Subgroup 1        Subgroup 2
  --------------------------- ------------------------------------------- --------------------- ----------------- -------------------
  Number of patients                                                      10,953                47                8
                              \% compared to all cancer patients          \-                    0.43%             0.07%
                              \% compared to subgroup 1                   \-                    \-                17.02%
  Number of samples                                                       10,967                48                8
                              \% compared to all cancer patients                                0.44%             0.07%
                              \% compared to subgroup 1                   \-                    \-                16.67%
  Diagnosis age (mean ± SD)                                               59.1 ± 14.5           66 ± 12.8         66.3 ± 7.8
                              *p*-value compared to all cancer patients                         **0.000742**      0.093018
                              *p*-value compared to subgroup 1            \-                    **-**             0.477389
  Sex, *N* (%)                Male                                        4866 (44.4%)          18 (37.5%)        3 (37.5%)
                              Female                                      5315 (48.5%)          27 (56.2%)        4 (50.0%)
                              NA                                          772 (7.0%)            3 (6.3%)          1 (12.5%)
                              Total                                       10,953                48                8
                              *p*-value compared to all cancer patients   \-                    0.30              0.79
                              *p*-value compared to subgroup 1            \-                    \-                0.89
  Mutation count              \<100                                       6798 (67.3%)          4 (8.3%)          0 (0%)
                              100 ≤ x \< 200                              1516 (15.0%)          2 (4.2%)          0 (0%)
                              200 ≤ x \< 280                              455 (4.5%)            2 (4.2%)          0 (0%)
                              \>280                                       1328 (13.2%)          40 (83.3%)        8 (100%)
                              Total                                       10,097 (100%)         48                8
                              *p*-value compared to all cancer patients   \-                    **\<0.00001**     **2.3 × 10^−11^**
                              *p*-value compared to subgroup 1            \-                    \-                0.67
  Cancer type, *N* (%)        Invasive breast carcinoma                   1084 (9.9%)           0 (0%)            0 (0%)
                              Non-small cell lung cancer                  1053 (9.6%)           8 (16.7%)         1 (12.5%)
                              Colorectal adenocarcinoma                   594 (5.4%)            2 (4.2%)          1 (12.5%)
                              Glioblastoma                                592 (5.4%)            0 (0%)            0 (0%)
                              Endometrial carcinoma                       586 (5.3%)            16 (33.3%)        2 (25.0%)
                              Ovarian epithelial tumor                    585 (5.3%)            1 (2.1%)          0
                              Head and neck squamous cell carcinoma       523 (4.8%)            1 (2.1%)          1 (12.5%)
                              Esophagogastric adenocarcinoma              514 (4.7%)            5 (10.4%)         1 (12.5%)
                              Diffuse glioma                              513 (4.7%)            0 (0%)            0 (0%)
                              Renal clear cell carcinoma                  512 (4.7%)            1 (2.1%)          0 (0%)
                              Well-differentiated thyroid                 500 (4.6%)            0 (0%)            0 (0%)
                              Prostate adenocarcinoma                     494 (4.5%)            0 (0%)            0 (0%)
                              Melanoma                                    448 (4.1%)            5 (10.4%)         0 (0%)
                              Bladder urothelial carcinoma                411 (3.7%)            2 (4.2%)          0 (0%)
                              Hepatocellular carcinoma                    369 (3.4%)            0 (0%)            0 (0%)
                              Renal non-clear cell carcinoma              348 (3.2%)            3 (6.3%)          1 (12.5%)
                              Sarcoma                                     255 (2.3%)            1 (2.1%)          0 (0%)
                              Cervical squamous cell carcinoma            251 (2.3%)            1 (2.1%)          1 (12.5%)
                              Leukemia                                    200 (1.8%)            0 (0%)            0 (0%)
                              Pancreatic adenocarcinoma                   184 (1.7%)            0 (0%)            0 (0%)
                              Pheochromocytoma                            147 (1.3%)            0 (0%)            0 (0%)
                              Thymic epithelial tumor                     123 (1.1%)            0 (0%)            0 (0%)
                              Esophageal squamous cell carcinoma          95 (0.9%)             1 (2.1%)          0 (0%)
                              Adrenocortical carcinoma                    92 (0.8%)             0 (0%)            0 (0%)
                              Pleural mesothelioma                        87 (0.8%)             0 (0%)            0 (0%)
                              Non-seminomatous germ cell tumor            86 (0.8%)             0 (0%)            0 (0%)
                              Ocular melanoma                             80 (0.7%)             0 (0%)            0 (0%)
                              Seminoma                                    63 (0.6%)             0 (0%)            0 (0%)
                              Mature B-cell neoplasms                     48 (0.4%)             0 (0%)            0 (0%)
                              Cervical adenocarcinoma                     46 (0.4%)             0 (0%)            0 (0%)
                              Cholangiocarcinoma                          36 (0.3%)             0 (0%)            0 (0%)
                              Miscellaneous neuroepithelial tumor         31 (0.3%)             0 (0%)            0 (0%)
                              Undifferentiated stomach adenocarcinoma     13 (0.1%)             1 (2.1%)          0 (0%)
                              Fibrolamellar carcinoma                     3 (\<0.1%)            0 (0%)            0 (0%)
                              Encapsulated glioma                         1 (\<0.1%)            0 (0%)            0 (0%)
                              Total                                       10,967                48                8
                              *p*-value compared to all cancer patients   \-                    **6 × 10^−12^**   0.96
                              *p*-value compared to subgroup 1            \-                    \-                NA

Subgroup 1: carriers of *PRNP* somatic mutations. Subgroup 2: carriers of *PRNP* pathogenic somatic mutations of prion disease. NA: not available. Shaded boxes indicate pathogenic somatic mutations of prion disease. Bold text indicates statistical significance (*p* \< 0.05).
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###### 

*In silico* annotations of *PRNP* somatic mutations in cancer patients.

  Mutations         PolyPhen-2   PANTHER             PROVEAN                                
  ----------------- ------------ ------------------- --------- ------------------- -------- -------------
  ^\$^ G5A          0.729        Possibly damaging   176       Probably benign     −1.238   Neutral
  ^\$^ L11I         0.161        Benign              176       Probably benign     −0.306   Neutral
  ^\$^ W16S         0.546        Possibly damaging   176       Probably benign     −1.237   Neutral
  ^\#^ S17G         0.528        Possibly damaging   176       Probably benign     −0.239   Neutral
  ^\$^ D18N         1.000        Probably damaging   176       Probably benign     −0.104   Neutral
  ^\$^ R25C         1.000        Probably damaging   176       Probably benign     −1.801   Neutral
  ^\$^ P26L         0.995        Probably damaging   324       Possibly damaging   −3.263   Deleterious
  ^\$^ G34R         1.000        Probably damaging   220       Possibly damaging   −3.889   Deleterious
  ^\#^ P39L         1.000        Probably damaging   361       Possibly damaging   −4.000   Deleterious
  ^\$^ Y49C         1.000        Probably damaging   176       Probably benign     −2.222   Neutral
  ^\$^ H61Y         0.975        Probably damaging   176       Probably benign     −1.021   Neutral
  ^\$^ H85N         0.975        Probably damaging   176       Probably benign     −0.833   Neutral
  ^\$^ G86S         1.000        Probably damaging   324       Possibly damaging   −0.995   Neutral
  ^\$^ G92E         1.000        Probably damaging   176       Probably benign     −1.253   Neutral
  ^\#^ P102L        1.000        Probably damaging   361       Possibly damaging   −3.392   Deleterious
  ^\#^ P105L        1.000        Probably damaging   324       Possibly damaging   −3.271   Deleterious
  ^\#^ P105T        0.998        Probably damaging   324       Possibly damaging   −2.333   Neutral
  ^\#^ P105S        0.997        Probably damaging   324       Possibly damaging   −1.496   Neutral
  ^\$^ K104E        0.974        Probably damaging   324       Possibly damaging   −1.208   Neutral
  ^\#^ G114V        1.000        Probably damaging   220       Possibly damaging   −2.540   Deleterious
  ^\#^ A117V        0.999        Probably damaging   176       Probably benign     −1.263   Neutral
  ^\$^ G119R        1.000        Probably damaging   361       Possibly damaging   −2.586   Deleterious
  ^\$^ L125F        1.000        Probably damaging   324       Possibly damaging   −0.398   Neutral
  ^\$^ M129T        0.181        Benign              324       Possibly damaging   −1.156   Neutral
  ^\$^ G131R        1.000        Probably damaging   361       Possibly damaging   −2.451   Neutral
  ^\#,\$^ G131V     1.000        Probably damaging   361       Possibly damaging   −2.879   Deleterious
  ^\$^ Y145C        0.997        Probably damaging   220       Possibly damaging   −1.742   Neutral
  ^\$^ E146Q        0.992        Probably damaging   361       Possibly damaging   −0.985   Neutral
  ^\$^ R148H        1.000        Probably damaging   361       Possibly damaging   −1.735   Neutral
  ^\$^ R151C        0.009        Benign              220       Possibly damaging   −2.016   Neutral
  ^\$^ M166I        0.000        Benign              30        Probably benign     0.254    Neutral
  ^\#,\$^ D167N     0.001        Benign              220       Possibly damaging   −0.631   Neutral
  ^\$^ N173H        0.952        Probably damaging   176       Probably benign     −1.573   Neutral
  ^\#^ V176G        0.998        Probably damaging   361       Possibly damaging   −2.253   Neutral
  ^\$^ H177N        0.313        Benign              220       Possibly damaging   −0.455   Neutral
  ^\#^ D178N-129M   1.000        Probably damaging   361       Possibly damaging   −1.531   Neutral
  ^\#^ D178N-129V   1.000        Probably damaging   361       Possibly damaging   −1.451   Neutral
  ^\#,\$^ V180I     0.009        Benign              220       Possibly damaging   −0.11    Neutral
  ^\#^ T183A        0.978        Probably damaging   324       Possibly damaging   −1.785   Neutral
  ^\#^ H187R        0.989        Probably damaging   220       Possibly damaging   −2.607   Deleterious
  ^\#^ T188K        0.996        Probably damaging   324       Possibly damaging   −0.550   Neutral
  ^\#^ E196K        0.624        Possibly damaging   220       Possibly damaging   −0.641   Neutral
  ^\#^ E196A        0.472        Possibly damaging   220       Possibly damaging   −1.206   Neutral
  ^\#^ F198S        0.994        Probably damaging   220       Possibly damaging   −0.792   Neutral
  ^\#^ E200K        0.995        Probably damaging   361       Possibly damaging   −1.478   Neutral
  ^\#^ E200G        0.994        Probably damaging   361       Possibly damaging   −3.245   Deleterious
  ^\#,\$^ D202N     1.000        Probably damaging   220       Possibly damaging   −1.118   Neutral
  ^\#,\$^ V203I     0.001        Benign              176       Probably benign     −0.004   Neutral
  ^\$^ K204N        0.898        Possibly damaging   220       Possibly damaging   −1.815   Neutral
  ^\#,\$^ R208C     1.000        Probably damaging   220       Possibly damaging   −2.324   Neutral
  ^\#,\$^ R208H     0.999        Probably damaging   220       Possibly damaging   −0.855   Neutral
  ^\$^ V209M        0.613        Possibly damaging   324       Possibly damaging   −1.03    Neutral
  ^\#^ V210I        0.803        Possibly damaging   220       Possibly damaging   0.039    Neutral
  ^\#,\$^ E211Q     0.992        Probably damaging   220       Possibly damaging   −0.36    Neutral
  ^\#^ Q212P        0.930        Possibly damaging   220       Possibly damaging   −1.665   Neutral
  ^\$^ C214G        0.975        Probably damaging   361       Possibly damaging   −4.402   Deleterious
  ^\#^ I215V        0.000        Benign              220       Possibly damaging   −0.099   Neutral
  ^\#^ Q217R        0.961        Probably damaging   220       Possibly damaging   −1.306   Neutral
  ^\$^ Q217K        0.942        Probably damaging   220       Possibly damaging   −1.186   Neutral
  ^\$^ Y218C        1.000        Probably damaging   361       Possibly damaging   −3.626   Deleterious
  ^\$^ E221G        0.651        Possibly damaging   220       Possibly damaging   −1.244   Neutral
  ^\$^ S230L        0.947        Possibly damaging   97        Probably benign     −1.372   Neutral
  ^\#^ M232R        0.082        Benign              91        Probably benign     −1.167   Neutral
  ^\#^ M232T        0.000        Benign              91        Probably benign     −0.825   Neutral
  ^\#^ P238S        1.000        Probably damaging   361       Possibly damaging   −1.189   Neutral
  ^\$^ I244F        0.001        Benign              176       Probably benign     −0.939   Neutral
  ^\$^ V252L        0.990        Probably damaging   176       Probably benign     −0.411   Neutral

^\$^ indicates somatic mutations of the *PRNP* gene in cancer patients. ^\#^ indicates previously reported pathogenic mutations of the *PRNP* gene in prion diseases. Shaded boxes indicate the mutations that were predicted to be deleterious by all three programs.
